Tolvaptan
Tolvaptan is in clinical trials to decrease kidney cysts; it suppresses vasopressin, a cyst growth trigger.
Drinking copious amounts of water, enough to exceed serum osmolality or about 3 liters/day, also
suppresses vasopressin. Caffeine increases cyclicAMP, which in turn increases vasopressin.
Tolvaptan"s side effects include increased thirst and increased urine output 4-5 liters per day
(quarts). Individuals taking tolvaptan must keep up with this fluid loss. It has been found safe
and effective in congestive heart failure and cirrhosis of the liver. TEMPO Phase II (2) the
open label study, (every participant receives tolvaptan) is well underway. In the double blind
study, phase III (3) some individuals receive tolvaptan others do not. Additional Tolvaptan trials have begun, including one by DaVita.
Tolvaptan Inclusion - exclusion
- PKD, no other diseases
- age 18 - 50 years of age
- no other medications other than blood pressure
- good kidney functioning - serum creatinine of 1.5 or less
- Large kidney volume greater than 1000 cc
This third phase is to determine if Tolvaptan is
effective in diminishing kidney cyst growth with PKD polycystic kidney disease. For
this 1000 to 3000 volunteers will be needed to complete the
fast track FDA approval granted by
the FDA. Tolvaptan, a vasopressin 2 blocking drug for polycystic kidney disease is useful for
both ADPKD, the autosomal dominant version and ARPKD, the autosomal recessive version.
Tolvaptan (Otsuka Maryland
Research Institute): Tolvaptan recently received fast track
designation by the Food and Drug Administration because of its promise as a treatment for PKD.
Tolvaptan a vasopressin inhibitor; a V2 Receptor blocker or a V2 drug. Surrounding kidney cysts
is vasopressin and cyclic AMP. This triggers kidney cysts to fill with fluid, triggering kidney
cyst expansion and growth. You may be wondering what can stimulate cyclic AMP to start this
process causing kidney cysts to expand, fill with fluid and to multiply in numbers?
Caffeine–caffeine from chocolate, de-caf coffee, de-caf tea, black tea, green tea, white tea,
coffee in all its forms and all other products containing caffeine stimulates
cyclic AMP.
With congestive heart failure diuretics are useful but can lead to kidney problems. OPC 41061 or
OPC 31026 (Tolvaptan) reduces fluid buildup, but it works differently from diuretics. OPC 41061
impedes the action of proteins in the kidney called vasopressin V2 receptors. These molecules
respond to the hormone vasopressin, which signals cells to take up water. Blocking V2 receptors
prevents fluid from accumulating. In addition to keeping patients on the dry side, tolvaptan
also appears to stabilize salt imbalances, or hyponatremia (low sodium). Hyponatremia is an
important predictor of poor outcomes in heart failure patients. To date doctors have no drugs to
treat this condition -- a fact that could hasten the arrival of tolvaptan. Common side effects
from OPC 31260 (the mother drug) are dry mouth, thirst, and increased urination.
Possible things researchers will be looking at with Tolvaptan:
- Diminishes cyst fluid without damaging kidneys
- Increases urine production
- Enhanced renal blood flow
- Increased glomerular filtration rate (GFR)
- Decreased renal vascular resistance
- Reduction of renal cyclic AMP (increased by caffeine intake)
- Prevention of renal enlargement
- Protection of renal function
- Inhibition of kidney cyst growth
Tolvaptan looks promising as a treatment for ADPKD, though it remains in clinical trials.